871 related articles for article (PubMed ID: 9619798)
1. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors.
Carr A; Samaras K; Burton S; Law M; Freund J; Chisholm DJ; Cooper DA
AIDS; 1998 May; 12(7):F51-8. PubMed ID: 9619798
[TBL] [Abstract][Full Text] [Related]
2. Clinical lipoatrophy in HIV-1 patients on HAART is not associated with increased abdominal girth, hyperlipidaemia or glucose intolerance.
Worm D; Kirk O; Andersen O; Vinten J; Gerstoft J; Katzenstein TL; Nielsen H; Pedersen C
HIV Med; 2002 Oct; 3(4):239-46. PubMed ID: 12444941
[TBL] [Abstract][Full Text] [Related]
3. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study.
Périard D; Telenti A; Sudre P; Cheseaux JJ; Halfon P; Reymond MJ; Marcovina SM; Glauser MP; Nicod P; Darioli R; Mooser V
Circulation; 1999 Aug; 100(7):700-5. PubMed ID: 10449690
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study.
Carr A; Samaras K; Thorisdottir A; Kaufmann GR; Chisholm DJ; Cooper DA
Lancet; 1999 Jun; 353(9170):2093-9. PubMed ID: 10382692
[TBL] [Abstract][Full Text] [Related]
5. Hyperlipidemia associated with the use of protease inhibitors.
Smith JH; Martin GJ; Decker CF
Clin Infect Dis; 2000 Jul; 31(1):207-8. PubMed ID: 10913432
[No Abstract] [Full Text] [Related]
6. Altered myocellular and abdominal fat partitioning predict disturbance in insulin action in HIV protease inhibitor-related lipodystrophy.
Gan SK; Samaras K; Thompson CH; Kraegen EW; Carr A; Cooper DA; Chisholm DJ
Diabetes; 2002 Nov; 51(11):3163-9. PubMed ID: 12401706
[TBL] [Abstract][Full Text] [Related]
7. [Diabetes and hyperglycemia in patients under treatment for HIV infection with the protease inhibitors indavir, ritonavir, saquinavir as well as nelfinavir (in development, but not yet released].
Pharm Unserer Zeit; 1997 Dec; 26(6):317. PubMed ID: 9513575
[No Abstract] [Full Text] [Related]
8. Efficacy and tolerability of pravastatin for the treatment of HIV-1 protease inhibitor-associated hyperlipidaemia: a pilot study.
Baldini F; Di Giambenedetto S; Cingolani A; Murri R; Ammassari A; De Luca A
AIDS; 2000 Jul; 14(11):1660-2. PubMed ID: 10983656
[No Abstract] [Full Text] [Related]
9. Fat distribution and metabolic changes are strongly correlated and energy expenditure is increased in the HIV lipodystrophy syndrome.
Kosmiski LA; Kuritzkes DR; Lichtenstein KA; Glueck DH; Gourley PJ; Stamm ER; Scherzinger AL; Eckel RH
AIDS; 2001 Oct; 15(15):1993-2000. PubMed ID: 11600828
[TBL] [Abstract][Full Text] [Related]
10. HIV protease inhibitors: advances in therapy and adverse reactions, including metabolic complications.
Kaul DR; Cinti SK; Carver PL; Kazanjian PH
Pharmacotherapy; 1999 Mar; 19(3):281-98. PubMed ID: 10221367
[TBL] [Abstract][Full Text] [Related]
11. The effects of antiretroviral protease inhibitors on serum lipid levels in HIV-infected patients.
Chang ES; Tetreault DD; Liu YT; Beall GN
J Am Diet Assoc; 2001 Jun; 101(6):687-9. PubMed ID: 11424549
[No Abstract] [Full Text] [Related]
12. The safety and antiviral effect of protease inhibitors in children.
Temple ME; Koranyi KI; Nahata MC
Pharmacotherapy; 2001 Mar; 21(3):287-94. PubMed ID: 11253853
[TBL] [Abstract][Full Text] [Related]
13. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome.
Carr A; Miller J; Law M; Cooper DA
AIDS; 2000 Feb; 14(3):F25-32. PubMed ID: 10716495
[TBL] [Abstract][Full Text] [Related]
14. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy.
Saint-Marc T; Partisani M; Poizot-Martin I; Bruno F; Rouviere O; Lang JM; Gastaut JA; Touraine JL
AIDS; 1999 Sep; 13(13):1659-67. PubMed ID: 10509567
[TBL] [Abstract][Full Text] [Related]
15. Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate.
Manfredi R; Chiodo F
J Infect; 2001 Apr; 42(3):181-8. PubMed ID: 11545549
[TBL] [Abstract][Full Text] [Related]
16. HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study.
Carr A; Hudson J; Chuah J; Mallal S; Law M; Hoy J; Doong N; French M; Smith D; Cooper DA;
AIDS; 2001 Sep; 15(14):1811-22. PubMed ID: 11579243
[TBL] [Abstract][Full Text] [Related]
17. Insulin resistance in HIV protease inhibitor-associated diabetes.
Yarasheski KE; Tebas P; Sigmund C; Dagogo-Jack S; Bohrer A; Turk J; Halban PA; Cryer PE; Powderly WG
J Acquir Immune Defic Syndr; 1999 Jul; 21(3):209-16. PubMed ID: 10421244
[TBL] [Abstract][Full Text] [Related]
18. Incidence of adverse reactions in HIV patients treated with protease inhibitors: a cohort study. Coordinamento Italiano Studio Allergia e Infezione da HIV (CISAI) Group.
Bonfanti P; Valsecchi L; Parazzini F; Carradori S; Pusterla L; Fortuna P; Timillero L; Alessi F; Ghiselli G; Gabbuti A; Di Cintio E; Martinelli C; Faggion I; Landonio S; Quirino T
J Acquir Immune Defic Syndr; 2000 Mar; 23(3):236-45. PubMed ID: 10839659
[TBL] [Abstract][Full Text] [Related]
19. Effect of protease inhibitors on the sense of taste.
Schiffman SS; Zervakis J; Heffron S; Heald AE
Nutrition; 1999 Oct; 15(10):767-72. PubMed ID: 10501290
[TBL] [Abstract][Full Text] [Related]
20. Lipodystrophic syndromes and hyperlipidemia in a cohort of HIV-1-infected patients receiving triple combination antiretroviral therapy with a protease inhibitor.
Rakotoambinina B; Médioni J; Rabian C; Jubault V; Jais JP; Viard JP
J Acquir Immune Defic Syndr; 2001 Aug; 27(5):443-9. PubMed ID: 11511820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
